The role of treat-to-target in inflammatory arthritis: Addressing cardiovascular risk and evaluating the benefit-risk profile of upadacitinib

In this article, Professor Tam discusses her management approach to optimising outcomes in patients with inflammatory arthritis. She explores the role of the treat-to-target approach, emphasizes the importance of early disease control in reducing cardiovascular risk and evaluates the benefit-risk analysis of upadacitinib.